Pipeline advancement - Higher R&D expenses attributed to progress in pivotal Phase 3 studies and regulatory filings for deucrictibant
Pre-commercial activities - Increased G&A spending linked to preparations for potential U.S. launch and expanded organizational structure
Q2 loss narrows as cash rises
Switzerland biopharma firm reported Q2 loss per share of €0.70, improving from prior year
Cash and equivalents rose to €318 mln, with runway extended into 2028 after $132 mln offering
R&D and G&A expenses increased as late-stage clinical programs advanced
Analyst coverage and valuation
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Pharvaris N.V. is $46.00, about 33.6% above its August 11 closing price of $34.42
Outlook for clinical and regulatory milestones
Pharvaris expects topline data from CHAPTER-3 Phase 3 study in 3Q2026
PHVS•
